Next-Generation Immunotherapies for Pseudomonas aeruginosa: Monoclonal Antibodies and Immune Checkpoint Modulation

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2026-10-26 DOI:10.1111/apm.70275
Muhammad Shahid Mehmood, Taimoor Wajid, Muhammad Saleem, Rida Khalid, Muhammad Husnain Mumtaz
{"title":"Next-Generation Immunotherapies for Pseudomonas aeruginosa: Monoclonal Antibodies and Immune Checkpoint Modulation","authors":"Muhammad Shahid Mehmood,&nbsp;Taimoor Wajid,&nbsp;Muhammad Saleem,&nbsp;Rida Khalid,&nbsp;Muhammad Husnain Mumtaz","doi":"10.1111/apm.70275","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p><i>Pseudomonas aeruginosa</i> represents a critical healthcare challenge, accounting for 7%–10% of hospital-acquired infections globally, with particularly high prevalence in intensive care, burn, and respiratory units, alongside escalating rates of multidrug-resistant and extensively drug-resistant strains. The bacterium evades host immunity through multiple mechanisms, including Type III Secretion System effector translocation and biofilm formation via polysaccharide matrices (alginate, Psl, Pel). Antibiotic-based therapies are increasingly ineffective, necessitating host-directed immunotherapeutic strategies. This review synthesizes emerging evidence on monoclonal antibody therapy and immune checkpoint modulation for <i>P. aeruginosa</i> infections. Bispecific antibodies targeting PcrV and Psl enhance opsonophagocytic killing and biofilm disruption through Fc-mediated mechanisms. Immune checkpoint inhibitors (anti-PD-1/PD-L1) reverse T-cell exhaustion from chronic antigen exposure and LPS-driven upregulation of inhibitory receptors, restoring antimicrobial function. Combination approaches integrating mAbs with antibiotics and checkpoint blockade show potential for synergistic bacterial clearance in preclinical pneumonia and burn wound models. Clinical translation remains limited by antigen variability (Psl and PcrV epitope polymorphisms), biofilm heterogeneity, and host immunogenetic diversity (Fc receptor polymorphisms, HLA variants, cytokine profiles). Multi-omics profiling may enable personalized treatment selection. Safety concerns regarding immune hyperactivation require carefully dosed, biomarker-guided strategies. Future development demands genomic stratification of responders and optimized therapeutic windows for maximal clinical benefit.</p>\n </div>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"134 11","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.70275","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pseudomonas aeruginosa represents a critical healthcare challenge, accounting for 7%–10% of hospital-acquired infections globally, with particularly high prevalence in intensive care, burn, and respiratory units, alongside escalating rates of multidrug-resistant and extensively drug-resistant strains. The bacterium evades host immunity through multiple mechanisms, including Type III Secretion System effector translocation and biofilm formation via polysaccharide matrices (alginate, Psl, Pel). Antibiotic-based therapies are increasingly ineffective, necessitating host-directed immunotherapeutic strategies. This review synthesizes emerging evidence on monoclonal antibody therapy and immune checkpoint modulation for P. aeruginosa infections. Bispecific antibodies targeting PcrV and Psl enhance opsonophagocytic killing and biofilm disruption through Fc-mediated mechanisms. Immune checkpoint inhibitors (anti-PD-1/PD-L1) reverse T-cell exhaustion from chronic antigen exposure and LPS-driven upregulation of inhibitory receptors, restoring antimicrobial function. Combination approaches integrating mAbs with antibiotics and checkpoint blockade show potential for synergistic bacterial clearance in preclinical pneumonia and burn wound models. Clinical translation remains limited by antigen variability (Psl and PcrV epitope polymorphisms), biofilm heterogeneity, and host immunogenetic diversity (Fc receptor polymorphisms, HLA variants, cytokine profiles). Multi-omics profiling may enable personalized treatment selection. Safety concerns regarding immune hyperactivation require carefully dosed, biomarker-guided strategies. Future development demands genomic stratification of responders and optimized therapeutic windows for maximal clinical benefit.

下一代铜绿假单胞菌的免疫治疗:单克隆抗体和免疫检查点调节
铜绿假单胞菌是一项重大的卫生保健挑战,占全球医院获得性感染的7%-10%,在重症监护、烧伤和呼吸部门的发病率特别高,同时耐多药和广泛耐药菌株的发病率也在不断上升。该细菌通过多种机制逃避宿主免疫,包括III型分泌系统效应物易位和通过多糖基质(海藻酸盐、Psl、Pel)形成生物膜。基于抗生素的治疗越来越无效,需要宿主导向的免疫治疗策略。本文综述了铜绿假单胞菌感染的单克隆抗体治疗和免疫检查点调节的新证据。靶向PcrV和Psl的双特异性抗体通过fc介导的机制增强调理吞噬细胞杀伤和生物膜破坏。免疫检查点抑制剂(抗pd -1/PD-L1)可逆转慢性抗原暴露导致的t细胞衰竭和lps驱动的抑制受体上调,恢复抗菌功能。将单克隆抗体与抗生素和检查点阻断相结合的联合方法在临床前肺炎和烧伤模型中显示出协同细菌清除的潜力。临床翻译仍然受到抗原变异(Psl和PcrV表位多态性)、生物膜异质性和宿主免疫遗传多样性(Fc受体多态性、HLA变异、细胞因子谱)的限制。多组学分析可以实现个性化的治疗选择。关于免疫过度激活的安全问题需要谨慎的剂量,生物标志物引导的策略。未来的发展需要对应答者进行基因组分层和优化治疗窗口,以获得最大的临床效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书